Showing Results for
- Academic Journals (31)
Search Results
- 31
Academic Journals
- 31
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedRecent patents regarding the preparation, amplification and therapeutic use of circular RNA. Author Affiliations: US 10,767,222 Methods for identifying sequence variants in a nucleic acid sample, comprising...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedAuthor(s): Neil Davey 1 , Randall Ray Rader 2 , Debabrata Chakravarti 3 Author Affiliations: (1) Harvard Law School, Cambridge, USA (2) The Rader Group, PLLC, Alexandria, USA (3) Department of Obstetrics and...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedEmergency Use Authorizations for two mRNA COVID-19 vaccines represent a turning point in the pandemic. They also herald a new era for vaccinology. Author Affiliations: One year ago, few would have tipped mRNA...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedAuthor(s): Christoph Bock 1 2 , Michael Boutros 3 , J. Gray Camp 4 , Laura Clarke 5 , Hans Clevers 6 7 , Juergen A. Knoblich 8 , Prisca Liberali 9 , Aviv Regev 10 11 , Anne C. Rios 6 12 13 , Oliver Stegle 14 15 ,...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedCurrent base editors (BEs) catalyze only base transitions (C to T and A to G) and cannot produce base transversions. Here we present BEs that cause C-to-A transversions in Escherichia coli and C-to-G transversions in...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedAuthor Affiliations: Boehringer Ingelheim has committed up to $1.45 billion, including milestones, to acquire NBE Therapeutics and its ROR1-targeted antibody-drug conjugate (ADC) NBE-002. The deal was inked just a...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedThe new drug not only is a boon for patients with spinal muscular atrophy, but also may spearhead the development of further chemical RNA modulators for a broad range of conditions. Author(s): Cormac Sheridan 1...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedEngineered SpCas9s and AsCas12a cleave fewer off-target genomic sites than wild-type (wt) Cas9. However, understanding their fidelity, mechanisms and cleavage outcomes requires systematic profiling across mispaired...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedAuthor(s): Wei Wu 1 2 3 , Diego A. Pizzagall 4 , Madhukar H. Trivedi 5 6 , Amit Etkin 1 2 3 Author Affiliations: (1) Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, USA (2) Wu...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedBy targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton's tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis. Author(s): Elie Dolgin 1...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedAuthor Affiliations: Nature Biotechnology's Irene Jarchum speaks with Michel Sadelain (pictured) about off-the-shelf CAR-T cells and discusses a recent paper from Maksim Mamonkin's group describing a clever strategy...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedComprehensive, high-quality reference genomes are required for functional characterization and taxonomic assignment of the human gut microbiota. We present the Unified Human Gastrointestinal Genome (UHGG) collection,...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedFollowing mixed results in the clinic against COVID-19, antibody engineers are further optimizing SARS-CoV-2 antibodies with the aim of improving outcomes. Author(s): Ken Garber 1 Author Affiliations: (1) Ann...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedNine dogs with hemophilia A were treated with adeno-associated viral (AAV) gene therapy and followed for up to 10 years. Administration of AAV8 or AAV9 vectors expressing canine factor VIII (AAV-cFVIII) corrected the...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedA correction to this paper has been published: https://doi.org/10.1038/s41587-020-00800-8 Author(s): Dennis Eriksson 1 , Eugénia de Andrade 2 , Borut Bohanec 3 , Sevasti Chatzopoulou 4 , Roberto Defez 5 , Nélida...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedInducible expression of neoantigens in mice would enable the study of endogenous antigen-specific naïve T cell responses in disease and infection, but has been difficult to generate because leaky antigen expression...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedBiosimilar manufacturing process patent applications first filed more than a year after the biologic is approved, which represent the largest source of patent assertions in biosimilar litigation, could be addressed...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedEngineered T cells are effective therapies against a range of malignancies, but current approaches rely on autologous T cells, which are difficult and expensive to manufacture. Efforts to develop potent allogeneic T...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedCRISPR-guided DNA cytosine and adenine base editors are widely used for many applications.sup.1-4 but primarily create DNA base transitions (that is, pyrimidine-to-pyrimidine or purine-to-purine). Here we describe the...
-
From:Nature Biotechnology (Vol. 39, Issue 1) Peer-ReviewedWe present Augur, a method to prioritize the cell types most responsive to biological perturbations in single-cell data. Augur employs a machine-learning framework to quantify the separability of perturbed and...